Business Wire

blnk Healthcare Extend Portfolio of Respirators and Face Masks

16.12.2020 15:49:00 EET | Business Wire | Press release

Share

With the end of the pandemic not in sight yet, TREKSTOR is announcing the expansion of its mask portfolio, therefore fulfilling the increased demand created by regulations and customers alike.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201216005568/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

blnk Type IIR disposable kids masks (Photo: Business Wire)

Some of the new entries are comprised of so-called filtering half-masks, commonly known as FFP2 and FFP3. The FFP2 masks with the model name BL-03N (item 30604) are packaged 2pcs per bag with the user manual directly printed on the outside. Comprised of 5 layers, the respirators have been type-approved by notified body SGS Fimko (0598) and are valid to use for 24 months from production. They are worn with ear-straps and come with a flexible nose guard included in the fabric.

Additionally, newly available are 20pcs boxes of two FFP3 masks with the model names LT-2020AP3 (item 30613) and LT-2020AP3V (item 30614), the later which includes a vent. Both masks are foldable, also include a nose-guard and are worn with elastic headbands, that can be adjusted to fit perfectly. Like all FFP3 masks, they filter ≥99% of particles, as has been confirmed by the notified body Applus (0370). This allows them to also be used in direct contact with COVID-19 positive patients.

„The demand for filtering half-masks has increased drastically over the last few weeks“, says Shimon Szmigiel, CEO of TREKSTOR. „Therefore, we decided to expand our portfolio beyond the already available KN95 respirators with CE approval based on EU guideline PPE-R 02.075.“

At the same time the face mask portfolio was updated. While the focus always has been on EN 14683:2019 certified masks of both types IIR and I, they were always only available for adults. But now TREKSTOR also offers type IIR face masks for children as well.

„Type IIR face masks filter ≥98% of exhaled air, therefore offering good protection for everyone around“, Simon Wiedemann, Head of Product Management explains. „With infections spreading in schools and day care centres more and more, wearing such masks consistently can help stop the spread of the virus dramatically.“

So kids can enjoy wearing a mask, TREKSTOR decided to offer them in 10 different designs, 5 each suited for boys and girls. Each design is packed 5pcs per re-sealable bag, if kids like to be surprised, the masks are also available in 5pcs mix packs with one mask of each design present within.

The kids masks are already in stock and can be ordered online at www.blnk-healthcare.com. The shop is also ready to accept pre-orders to FFP2 and FFP3 masks, which will then be fulfilled in early January. Interested parties can also declare their interest by sending an email to sales@blnk-healthcare.com. PR requests should be directed to pr@blnk-healthcare.com.

About TREKSTOR / blnk Healthcare

TREKSTOR, known as one of Europe’s leading consumer electronics manufacturers based in Bensheim, Germany, has been active in the healthcare space with its brand blnk starting March 2020, helping to stop the spread of the virus via face masks, disinfectants and other protective equipment. The company is selling equally to government institutions and the army alongside direct sales to care facilities, hospitals, pharmacies and end-consumers.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Simon Wiedemann
Head of Marketing and Product
pr@blnk-healthcare.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 11:00:00 EEST | Press release

Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S

European Commission Approves DAYBU ® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 10:01:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim

ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 09:36:00 EEST | Press release

Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly as possible. “Our discovery of the first orexin agonist is a successful representation of Japan-originated science that will directly impact people around the world living with narcolepsy type 1,” said Julie Kim, president and chief executive officer of Takeda. “With the potential to redefine narcolepsy type 1 care, ORZEYFUL is the first validation of our broader orexin strategy, demonstrating how scientifi

Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 09:03:00 EEST | Press release

Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial network that connects banks, telcos, payment and liquidity providers to enable settlement across international markets. Fasset will also increase investment in agentic AI-enabled systems supporting corridor banking, stablecoin settlement and tokenized asset infrastructure. After raising Series B in May, Fasset has now raised a total of $119 million in 2026. The financing marks Fasset’s entry into the glob

Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 08:11:00 EEST | Press release

Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye